CARB-X, a global biopharmaceutical accelerator, has awarded $2.6 million to the Netherlands-based company AdJane to advance its vaccine candidate against Neisseria gonorrhoeae. This funding addresses the urgent public health crisis of gonorrhea, which is becoming increasingly difficult to treat due to widespread antimicrobial resistance. The collaboration aims to develop a preventative solution to curb the spread of this common sexually transmitted infection and reduce reliance on antibiotics.
The Escalating Public Health Challenge
Gonorrhea represents a significant global health issue, with over 80 million new infections reported annually across the world. The bacterial infection can lead to severe long-term complications, including pelvic inflammatory disease, infertility, and a heightened risk of HIV transmission. A major challenge in controlling its spread is that many infections are asymptomatic, allowing the disease to be transmitted unknowingly.
The bacterium Neisseria gonorrhoeae is particularly problematic because it does not provoke a durable natural immune response in infected individuals. This lack of immunity leads to frequent reinfections, which in turn necessitates repeated courses of antibiotic treatment for patients. This cycle has been a primary driver in the evolution of drug-resistant strains, making the infection progressively harder to manage clinically.
An Innovative Vaccine Platform
AdJane is developing its vaccine using a proprietary native Outer Membrane Vesicle (nOMV) platform, which has already demonstrated a favorable safety profile in a Phase I human clinical trial. The company is employing a heterologous approach specifically for its gonorrhea candidate to generate a powerful and comprehensive immune response. This strategy is designed to overcome the challenges that have hindered previous vaccine development efforts for this complex bacterium.
The heterologous design combines a broad, platform-driven antigenic background with the targeted expression of multiple highly conserved gonococcal antigens. This innovative method aims to create a single-component vaccine that can deliver both broad and targeted immune protection against N. gonorrhoeae. According to AdJane, this approach also supports a more streamlined development and manufacturing process for the potential vaccine.
A Strategic Alliance Against Resistance
Leaders from both organizations highlighted the importance of this new funding in the global fight against antimicrobial resistance. Richard Alm, interim Chief of R&D at CARB-X, noted that AdJane's technically grounded strategy directly addresses key difficulties in generating protective immunity. He emphasized that a successful vaccine would be crucial for reducing infection rates and slowing the spread of resistant gonorrhea strains.
Anita Gashi, Managing Director of AdJane, expressed gratitude for the support, stating that the award recognizes the potential of their next-generation nOMV platform. She affirmed the company's vision to tackle major global health challenges like gonorrhea through this innovative technology. This award continues previous CARB-X support for the development of a vaccine to prevent the infection.
CARB-X's Global Impact on R&D
Since its establishment in 2016, CARB-X has played a pivotal role in revitalizing a stalled early-stage antibiotic research and development pipeline. The global non-profit partnership has supported 123 projects across 14 countries, focusing on innovative therapeutics, preventatives, and rapid diagnostics. Its mission is to fund projects targeting the most serious drug-resistant bacteria identified on global priority lists.
The accelerator's efforts have yielded significant progress, with 25 supported projects advancing to or completing clinical trials and three products successfully reaching the market. Furthermore, CARB-X ensures its partners commit to responsible stewardship and access plans for low- and middle-income countries. This comprehensive approach helps secure the long-term viability and global availability of new antibacterial products.
This $2.6 million award from CARB-X to AdJane marks a significant investment in a promising preventative strategy against drug-resistant gonorrhea. By supporting the development of an innovative nOMV-based vaccine, this partnership aims to address a critical gap in public health and reduce the world's dependence on antibiotics. The success of this project could provide a vital new tool in the global effort to control sexually transmitted infections and combat antimicrobial resistance.